Chattanooga, Tenn. – The Erlanger Heart and Lung Institute welcomes Megan Coylewright, MD, MPH, FSCAI, FACC, to its team of exceptional cardiology providers as Director of the Structural Heart Program. In this role, Dr. Coylewright will lead a highly skilled team that treats valvular and structural heart disease while expanding access to state-of-the-art cardiovascular device clinical trials in the region.
Dr. Coylewright is board-certified in the areas of cardiology and interventional cardiology. As a structural interventionalist, she performs minimally invasive valve repair and replacement, offering alternatives to traditional surgery. Her expertise includes transcatheter aortic valve replacement (TAVR), including expanded options for patients with diseased blood vessels or failed surgical valves.
Most recently, Dr. Coylewright served as attending physician and associate professor of cardiovascular medicine at Dartmouth-Hitchcock Medical Center. In this role, Dr. Coylewright founded the transcatheter mitral and tricuspid valve repair programs. She also has a passion for stroke prevention and performs two minimally-invasive procedures to reduce the risk of stroke (Watchman, PFO closure). She is a mentor to medical students, residents and fellows, and she was awarded the Department of Medicine teaching award for her work at Dartmouth.
“We are excited to welcome Dr. Coylewright and her wealth of knowledge and experience in structural interventional cardiology to the Erlanger Heart and Lung institute,” said Senior Director of Cardiovascular Services Cheryl Wieber. “Dr. Coylewright’s dedication to patient experience, exceptional outcomes, research and genuine patient servitude is why she is highly regarded within the cardiovascular community and beyond.”
Dr. Coylewright received her medical degree, Master of Public Health and residency training at Johns Hopkins in Baltimore, Md. While there, she also served as the Health Disparities Coordinator at the Baltimore City Public Health Department. She completed an additional five years of fellowship training in cardiology, interventional cardiology, and structural heart interventions at Mayo Clinic in Rochester, Minn.
Dr. Coylewright is the recipient of many grants for research. This includes testing the newest, state-of-the-art therapies for heart valve disease that may not be available at all medical centers. She is also funded for her research in shared decision-making, with a focus on identifying innovations in patient-centered care.
“Dr. Coylewright is an advocate for consistent care across all platforms and for all types of patients,” said Wieber. “We have no doubt she will do a superb job of enacting Erlanger’s mission of compassionately caring for patients.”
For more information about the Erlanger Heart and Lung Institute, please visit erlanger.org/heart.